Marcoumar

Phenprocoumon, the active ingredient in Marcoumar, is a vitamin K antagonist anticoagulant presented as an oral formulation for oral use. It is employed to prevent and treat thromboembolic disorders, including stroke risk in atrial fibrillation and venous clot formation after orthopedic surgery.

GNH USA supplies Marcoumar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global healthcare providers.

Phenprocoumon is used as an oral anticoagulant to manage conditions associated with abnormal blood clot formation. - Thromboembolic disorders: reduces risk of clot formation and recurrence. - Atrial fibrillation: prevents stroke and systemic embolism in patients with non‑valvular atrial fibrillation. - Orthopedic surgery: lowers incidence of venous thromboembolism following hip or knee replacement procedures.

Phenprocoumon may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Minor bleeding: bruising, gum bleeding, or epistaxis. - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Skin reactions: rash or mild itching.

Serious or Rare Side Effects: - Major hemorrhage: intracranial, gastrointestinal or severe internal bleeding. - Skin necrosis: painful, purplish skin lesions that may progress. - Allergic reactions: anaphylaxis, angioedema, or severe urticaria. - Hepatotoxicity: elevated liver enzymes or liver injury (rare).

When prescribing phenprocoumon, clinicians should observe several safety measures to minimize bleeding risk and ensure therapeutic effectiveness. - Baseline assessment: obtain complete blood count and coagulation profile before initiation. - Dose adjustment: monitor INR regularly and adjust dose to maintain target therapeutic range. - Drug interactions: review concomitant medications that affect vitamin K metabolism or platelet function. - Patient education: advise avoidance of activities with high injury risk and inform about signs of bleeding. - Liver or kidney impairment: use caution and consider dose modification in patients with hepatic or renal dysfunction. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Phenprocoumon interacts with several medicines that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP2C9 inhibitors: amiodarone, fluconazole, or other potent inhibitors may markedly increase INR. - Antiplatelet agents: aspirin, clopidogrel can amplify bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): ibuprofen, naproxen may potentiate hemorrhage.

Moderate Interactions (Monitor Closely): - Vitamin K‑rich foods or supplements: leafy greens, warfarin‑containing herbal products can reduce efficacy. - Antibiotics affecting gut flora: broad‑spectrum agents like rifampin may lower INR. - Heparin or low‑molecular‑weight heparin: concurrent use requires careful coagulation monitoring.